Embedded Files
Creating a world without dementia
OUR TECHNOLOGY STACK
OUR TECHNOLOGY STACK
AI/ML based drug design
AI/ML based drug design
Our therapeutic candidates are based on custom AI/ML-based algorithms and pipelines. By integrating computational intelligence with biological insights, our proprietary algorithms analyze and predict codon usage, structural stability, and translational efficiency. This ensures that each mRNA/protein sequence is tailored for maximum functionality, enhanced stability, and optimal expression in target systems.
High content microscopy
High content microscopy
For our novel therapeutic candidates, we capture intricate, single-cell phenotypic changes – from neurite arborization and synaptic puncta density to mitochondrial health and protein localization. This granular, quantitative analysis allows us to precisely evaluate neuroprotective efficacy and pinpoint subtle indicators of neurotoxicity, accelerating the design of targeted and safer treatments for neurological disorders.
Patient derived iPSC neurons
Patient derived iPSC neurons
We leverage iPSC-derived cellular models to validate our RNA/protein therapeutics for dementia. By differentiating iPSCs into disease-relevant neuronal subtypes, we assess the pharmacodynamic and pharmacokinetic properties of our RNA/protein candidates in a biologically relevant system. This enables precise optimization of RNA/protein designs for improved stability, efficacy, and translational potential in neurodegenerative disease models.
OUR TEAM
OUR TEAM
Beeni Raj, PhD
Beeni Raj, PhD
Dr. Raj is a clinical neuropharmacologist with experience across several pharmaceutical companies. She holds a strong academic foundation from Harvard Medical School and the University of California, San Francisco. With deep expertise in biomarker and therapeutic development for neurodegenerative diseases, she integrates clinical insight with computational innovation to advance drug discovery.
Anuj Guruvacharya, PhD
Anuj Guruvacharya, PhD
Dr. Guruvacharya is a computational biologist. With a strong background in AI-driven drug discovery and neurodegeneration research, he specializes in developing scalable models to decode complex biological data. His previous experiences include working for various biotech companies in Washington D.C., for the cloud computing division within Amazon, and for Gilbert Family Foundation. He has a doctorate from University of Oklahoma.
James Goldn, PhD
James Goldn, PhD
Dr. Goldn has deep expertise in neural networks, computer vision, and natural language processing. With a strong academic foundation from Swarthmore, Cornell, and Stanford, James brings a unique interdisciplinary perspective to AI and machine learning. His latest job was at Amazon. Prior to joining Amazon, he conducted postdoctoral research in computational neuroscience and deep learning for medical imaging at UCSF and Stanford, contributing to both translational brain tumor research and vision science.
Ammasi Periasamy, PhD
Ammasi Periasamy, PhD
Dr. Periasamy is a Professor of Biology and Biomedical Engineering at the University of Virginia and the founding Director of the W.M. Keck Center for Cellular Imaging. An internationally recognized leader in advanced light microscopy, Dr. Periasamy pioneered the development of fluorescence lifetime imaging microscopy (FLIM) and FRET techniques for studying protein-protein interactions in living cells. His work bridges optical innovation with biomedical discovery, and he has authored over 100 publications, edited multiple books, and trained scientists globally through annual hands-on workshops in cellular imaging.
CONTACT
CONTACT
Nanil Therapeutics Inc.
407 9 Ave SE
Calgary, Alberta, T2G 2K7
Canada
Nanil Therapeutics LLC.
Embarcadero Center
San Francisco, CA 94111
USA
Page updated
Google Sites
Report abuse